Skip to main content
AmigoFish

201. Out of Cell Experience: Michael Heltzen Drives Pure Chemistry at eXoZymes

From Grow Everything Biotech Podcast · · 50 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Michael Heltzen, CEO of Exozymes, joins Grow Everything to explain how cell free biomanufacturing is opening new possibilities for natural products, nutraceuticals, and medicines. Michael shares why engineered enzymes can make high purity molecules without relying on living cells, how Exozymes moved its NCT program from discovery toward commercial manufacturing in less than two years, and why its capital light partnership model is central to scaling impact. The conversation also explores AI guided enzyme design, digital twins for manufacturing, rare cannabinoids, downstream processing, and the disciplined focus required to turn a broad biotechnology platform into real products.

Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and speak with the leaders and innovators using biology to change the world. Biology is the world’s oldest technology, and it can be engineered. So, what are we growing?

Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (http://www.messaginglab.com/groweverything)

Chapters:

- (00:00:00) Michael Heltzen and the Exozymes mission

- (00:05:00) Why cell free manufacturing can unlock inaccessible natural products

- (00:10:00) Combining molecular biology, computation, and AI guided enzyme design

- (00:15:00) From laboratory platform to industrial scale production

- (00:20:00) Commercial partnerships and the NCT market opportunity

- (00:25:00) Rare cannabinoids and a new toolkit for medicinal chemistry

- (00:30:00) The capital light licensing model for biomanufacturing

- (00:35:00) Downstream processing, purity, and investor skepticism

- (00:40:00) The future of sustainable enzyme driven chemical manufacturing

- (00:45:00) Key takeaways on focus, partnerships, and platform innovation

Links and Resources:

- eXoZymes⁠ (https://exozymes.com/)

- eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery (https://exozymes.com/blog/grant-cannabinoid-analogs)

- ⁠eXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical⁠ (https://www.genengnews.com/topics/bioprocessing/exozymes-cell-free-biomanufacturing-platform-gets-positive-feedback-from-cayman-chemical/)

- Michael Heltzen LinkedIn (https://www.linkedin.com/in/michaelheltzen)

- ⁠eXoZymes on LinkedIn⁠ (https://www.linkedin.com/company/exozymes/)

- 129. No Cells? No Problem! eXoZymes' Michael Heltzen on the Future of Microbe-Free Biotech (https://open.spotify.com/episode/7CsGbeOHzLUuU4HmTNaTXp?si=6YN4cX09Q5iaokcANyt_QQ)

- 176. Dare to Commercialize: Damien Perriman’s eXoZymes Playbook (https://open.spotify.com/episode/3K1lo3F76vbw2K2OIEWssy?si=87LDimQlQ5qxILlXFe0Gug)

- 51. Cell-Free, Problem-Free: Enzyme Alchemy with Alex Rosay at Cascade Biocatalysts (https://open.spotify.com/episode/7A8EHlPgs2TPOgAUrXreO7?si=j9uvLFCoRg2JFQns0XVDHw)

- 85. Always Be Brewing: Continuous Fermentation with Cauldron's Michele Stansfield (https://open.spotify.com/episode/1HD4TIJEKc3tYCGjy8lDkD?si=SsWy01YlQVGCt4q6bfWPpQ)

Topics Covered:

cell-free biomanufacturing, enzyme engineering, exozymes, biosynthesis, cannabinoids, NCT (N-trans-caffeoyltyramine), synthetic biology, AI-driven enzyme design, scalable bioproduction, sustainable chemicals

Have a question or comment? Message us here:

Text or Call (804) 505-5553

⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠ (https://www.instagram.com/groweverythingpod/) / ⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠ (https://twitter.com/messaginglab) / ⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ (https://www.linkedin.com/company/messaginglab/) / ⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠ (https://www.youtube.com/channel/UCyfFwKFgFVMfEz4VWYwL4fg) / ⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠ (https://www.messaginglab.com/groweverything)

Music by: Nihilore

Production by: Amplafy Media

Back to Grow Everything Biotech Podcast · Report a problem